Total Payments
$254.68
2022 Payments
$14.66
Companies
4
Transactions
21
Medicare Patients
3,878
Medicare Billing
$286,191
Payment Breakdown by Category
Food & Beverage$221.73 (87.1%)
Education$32.95 (12.9%)
Other$0.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $221.73 | 19 | 87.1% |
| Education | $32.95 | 2 | 12.9% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| GlaxoSmithKline, LLC. | $132.37 | 17 | $0 (2017) |
| Ethicon Inc. | $74.70 | 1 | $0 (2021) |
| CSL Behring | $32.95 | 2 | $0 (2018) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $14.66 | 1 | $0 (2022) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2022 | $14.66 | 1 | Boehringer Ingelheim Pharmaceuticals, Inc. ($14.66) |
| 2021 | $74.70 | 1 | Ethicon Inc. ($74.70) |
| 2018 | $32.95 | 2 | CSL Behring ($32.95) |
| 2017 | $132.37 | 17 | GlaxoSmithKline, LLC. ($132.37) |
All Payment Transactions
21 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/01/2022 | Boehringer Ingelheim Pharmaceuticals, Inc. | SPIRIVA RESPIMAT (Drug) | Food and Beverage | In-kind items and services | $14.66 | General |
| Category: RESPIRATORY | ||||||
| 07/01/2021 | Ethicon Inc. | Monarch Platform (Device) | Food and Beverage | In-kind items and services | $74.70 | General |
| Category: Endo-Mechanical | ||||||
| 03/20/2018 | CSL Behring | Zemaira (Biological) | Education | In-kind items and services | $20.00 | General |
| Category: Pulmonary/Respiratory Diseases | ||||||
| 03/20/2018 | CSL Behring | Zemaira (Biological) | Education | In-kind items and services | $12.95 | General |
| Category: Pulmonary/Respiratory Diseases | ||||||
| 11/30/2017 | GlaxoSmithKline, LLC. | BREO (Drug) | Food and Beverage | In-kind items and services | $4.84 | General |
| Category: RESPIRATORY | ||||||
| 11/30/2017 | GlaxoSmithKline, LLC. | BREO (Drug) | Food and Beverage | In-kind items and services | $2.34 | General |
| Category: RESPIRATORY | ||||||
| 11/29/2017 | GlaxoSmithKline, LLC. | BREO (Drug), INCRUSE | Food and Beverage | In-kind items and services | $16.36 | General |
| Category: RESPIRATORY | ||||||
| 11/15/2017 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug) | Food and Beverage | In-kind items and services | $6.37 | General |
| Category: RESPIRATORY | ||||||
| 10/25/2017 | GlaxoSmithKline, LLC. | BREO (Drug) | Food and Beverage | In-kind items and services | $7.47 | General |
| Category: RESPIRATORY | ||||||
| 10/10/2017 | GlaxoSmithKline, LLC. | ANORO (Drug) | Food and Beverage | In-kind items and services | $6.87 | General |
| Category: RESPIRATORY | ||||||
| 09/13/2017 | GlaxoSmithKline, LLC. | BREO (Drug) | Food and Beverage | In-kind items and services | $10.62 | General |
| Category: RESPIRATORY | ||||||
| 09/08/2017 | GlaxoSmithKline, LLC. | BREO (Drug) | Food and Beverage | In-kind items and services | $4.60 | General |
| Category: RESPIRATORY | ||||||
| 08/16/2017 | GlaxoSmithKline, LLC. | BREO (Drug) | Food and Beverage | In-kind items and services | $9.95 | General |
| Category: RESPIRATORY | ||||||
| 07/26/2017 | GlaxoSmithKline, LLC. | BREO (Drug) | Food and Beverage | In-kind items and services | $10.50 | General |
| Category: RESPIRATORY | ||||||
| 06/08/2017 | GlaxoSmithKline, LLC. | ANORO (Drug) | Food and Beverage | In-kind items and services | $6.81 | General |
| Category: RESPIRATORY | ||||||
| 05/31/2017 | GlaxoSmithKline, LLC. | BREO (Drug) | Food and Beverage | In-kind items and services | $13.35 | General |
| Category: RESPIRATORY | ||||||
| 05/17/2017 | GlaxoSmithKline, LLC. | ANORO (Drug) | Food and Beverage | In-kind items and services | $10.93 | General |
| Category: RESPIRATORY | ||||||
| 04/26/2017 | GlaxoSmithKline, LLC. | BREO (Drug) | Food and Beverage | In-kind items and services | $5.87 | General |
| Category: RESPIRATORY | ||||||
| 04/12/2017 | GlaxoSmithKline, LLC. | ANORO (Drug) | Food and Beverage | In-kind items and services | $6.08 | General |
| Category: RESPIRATORY | ||||||
| 03/22/2017 | GlaxoSmithKline, LLC. | ANORO (Drug), AMERGE | Food and Beverage | In-kind items and services | $3.36 | General |
| Category: RESPIRATORY | ||||||
| 01/25/2017 | GlaxoSmithKline, LLC. | BREO (Drug) | Food and Beverage | In-kind items and services | $6.05 | General |
| Category: RESPIRATORY | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 14 | 734 | 976 | $171,484 | $54,476 |
| 2022 | 13 | 856 | 1,131 | $176,156 | $60,210 |
| 2021 | 14 | 1,076 | 1,379 | $210,466 | $80,905 |
| 2020 | 16 | 1,212 | 1,582 | $228,177 | $90,600 |
Total Patients
3,878
Total Services
5,068
Medicare Billing
$286,191
Procedure Codes
57
All Medicare Procedures & Services
57 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 90 | 184 | $29,384 | $11,329 | 38.6% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2023 | 156 | 220 | $22,659 | $10,036 | 44.3% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 63 | 104 | $24,144 | $9,418 | 39.0% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 63 | 68 | $30,317 | $8,577 | 28.3% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 36 | 37 | $11,100 | $3,635 | 32.8% |
| 99231 | Subsequent hospital care with straightforward or low level of medical decision making, per day, if using time, at least 25 minutes | Facility | 2023 | 58 | 76 | $8,176 | $2,912 | 35.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 35 | 39 | $7,446 | $2,838 | 38.1% |
| 99291 | Critical care, first 30-74 minutes | Facility | 2023 | 12 | 18 | $20,694 | $2,816 | 13.6% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 12 | 13 | $4,098 | $1,252 | 30.6% |
| 94060 | Test to measure expiratory airflow and volume changes before and after medication administration | Facility | 2023 | 76 | 80 | $5,175 | $570.85 | 11.0% |
| 94726 | Test to determine lung volumes using sensors | Facility | 2023 | 54 | 56 | $3,080 | $463.29 | 15.0% |
| 94729 | Test to examine how well the lungs exchange gases | Facility | 2023 | 56 | 58 | $3,480 | $364.47 | 10.5% |
| 94618 | Test for exercise-induced lung stress | Facility | 2023 | 11 | 11 | $892.64 | $187.99 | 21.1% |
| 94010 | Test to measure expiratory airflow and volume | Facility | 2023 | 12 | 12 | $839.04 | $75.60 | 9.0% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 82 | 181 | $42,732 | $14,448 | 33.8% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 87 | 94 | $42,175 | $13,790 | 32.7% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2022 | 199 | 276 | $26,480 | $13,415 | 50.7% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 67 | 113 | $18,080 | $6,138 | 34.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 50 | 56 | $7,490 | $4,141 | 55.3% |
| 99291 | Critical care, first 30-74 minutes | Facility | 2022 | 13 | 15 | $9,379 | $2,371 | 25.3% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 16 | 17 | $5,100 | $1,755 | 34.4% |
| 99231 | Follow-up hospital inpatient care per day, typically 15 minutes | Facility | 2022 | 34 | 49 | $5,390 | $1,421 | 26.4% |
| 94060 | Test to measure expiratory airflow and volume changes before and after medication administration | Facility | 2022 | 100 | 110 | $6,600 | $839.90 | 12.7% |
| 94726 | Test to determine lung volumes using sensors | Facility | 2022 | 80 | 84 | $4,620 | $716.64 | 15.5% |
| 94729 | Test to examine how well the lungs exchange gases | Facility | 2022 | 83 | 87 | $5,220 | $551.24 | 10.6% |
About Dr. Cesar Munoz, M.D
Dr. Cesar Munoz, M.D is a Pulmonary Disease healthcare provider based in Chandler, Arizona. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 08/19/2005. The National Provider Identifier (NPI) number assigned to this provider is 1710979208.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Cesar Munoz, M.D has received a total of $254.68 in payments from pharmaceutical and medical device companies, with $14.66 received in 2022. These payments were reported across 21 transactions from 4 companies. The most common payment nature is "Food and Beverage" ($221.73).
As a Medicare-enrolled provider, Munoz has provided services to 3,878 Medicare beneficiaries, totaling 5,068 services with total Medicare billing of $286,191. Data is available for 4 years (2020–2023), covering 57 distinct procedure/service records.
Ad
Practice Information
- Specialty Pulmonary Disease
- Other Specialties Critical Care Medicine, Critical Care Medicine
- Location Chandler, AZ
- Active Since 08/19/2005
- Last Updated 01/29/2026
- Taxonomy Code 207RP1001X
- Entity Type Individual
- NPI Number 1710979208
Products in Payments
- BREO (Drug) $91.95
- Monarch Platform (Device) $74.70
- ANORO (Drug) $34.05
- Zemaira (Biological) $32.95
- SPIRIVA RESPIMAT (Drug) $14.66
- TRELEGY ELLIPTA (Drug) $6.37
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Pulmonary Disease Doctors in Chandler
Muhammad Salim, Md, MD
Pulmonary Disease — Payments: $11,684
Pulmonary Disease $11,684
Dr. Mhd-Iyad Saadi, Md, MD
Pulmonary Disease — Payments: $8,665
Pulmonary Disease $8,665
Loreto Sulit, Md, MD
Pulmonary Disease — Payments: $6,730
Pulmonary Disease $6,730
Mr. Salman Sheikh, Md, MD
Pulmonary Disease — Payments: $1,295
Pulmonary Disease $1,295
Pedro Quiroga, Md, MD
Pulmonary Disease — Payments: $732.94
Pulmonary Disease $732.94
Dr. Daniel Belen, Do, DO
Pulmonary Disease — Payments: $238.83
Pulmonary Disease $238.83